Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:OLMANASDAQ:ORMPNASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.42-2.4%$1.29$1.01▼$3.45$396.60M1.121.74 million shs4.01 million shsOLMAOlema Pharmaceuticals$5.32+0.4%$4.45$2.86▼$16.62$364M2.03854,527 shs361,610 shsORMPOramed Pharmaceuticals$2.35+5.4%$2.20$1.82▼$3.09$96.00M1.65152,814 shs229,413 shsSNDLSNDL$1.26-2.7%$1.36$1.24▼$2.40$332.33M3.682.01 million shs1.85 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca-2.41%+15.98%-3.08%+3.28%-41.29%OLMAOlema Pharmaceuticals+0.38%+5.56%+3.10%+21.74%-44.87%ORMPOramed Pharmaceuticals+5.38%+10.85%+1.29%+12.44%+7.80%SNDLSNDL-2.72%-1.96%-15.12%-21.45%-41.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.5974 of 5 stars4.51.00.00.03.42.51.3OLMAOlema Pharmaceuticals1.9349 of 5 stars3.51.00.00.02.82.50.0ORMPOramed Pharmaceuticals1.7683 of 5 stars0.04.00.00.02.70.81.9SNDLSNDL3.3634 of 5 stars3.54.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57223.07% UpsideOLMAOlema Pharmaceuticals 3.00Buy$24.50360.53% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ASNDLSNDL 3.00Buy$3.63186.63% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, ERAS, OLMA, and SNDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.003/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/21/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/19/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $25.003/19/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AORMPOramed Pharmaceuticals$2M48.00N/AN/A$4.04 per share0.58SNDLSNDL$927.61M0.36N/AN/A$3.47 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)OLMAOlema Pharmaceuticals-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/12/2025 (Estimated)ORMPOramed Pharmaceuticals$5.53M-$0.4421.36N/AN/AN/A-7.27%-6.20%8/13/2025 (Estimated)SNDLSNDL-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%8/7/2025 (Estimated)Latest ORMP, ERAS, OLMA, and SNDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/A3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00OLMAOlema PharmaceuticalsN/A7.107.10ORMPOramed PharmaceuticalsN/A27.0827.08SNDLSNDL0.105.614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%OLMAOlema Pharmaceuticals91.78%ORMPOramed Pharmaceuticals12.73%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipERASErasca14.40%OLMAOlema Pharmaceuticals19.40%ORMPOramed Pharmaceuticals13.70%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million221.94 millionOptionableOLMAOlema Pharmaceuticals7068.42 million46.18 millionOptionableORMPOramed Pharmaceuticals1040.85 million34.79 millionOptionableSNDLSNDL580262.78 millionN/AOptionableORMP, ERAS, OLMA, and SNDL HeadlinesRecent News About These CompaniesMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 612,495 Shares of SNDL Inc. (NASDAQ:SNDL)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in SNDL Inc. (NASDAQ:SNDL)May 21, 2025 | marketbeat.com1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court OrderMay 20, 2025 | finance.yahoo.comCanadian Securities Exchange Reports April 2025 Performance FiguresMay 15, 2025 | finance.yahoo.comBNP Paribas Financial Markets Makes New $7.36 Million Investment in SNDL Inc. (NASDAQ:SNDL)May 15, 2025 | marketbeat.comSA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLIMay 5, 2025 | msn.comSNDL (NASDAQ:SNDL) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSMay 5, 2025 | marketbeat.comSNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has IncreasedMay 5, 2025 | seekingalpha.comBoothbay Fund Management LLC Takes Position in SNDL Inc. (NASDAQ:SNDL)May 4, 2025 | marketbeat.comSNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.comSNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2025 | finance.yahoo.com3 Marijuana Stocks For The Long Term InvestingMay 2, 2025 | marijuanastocks.comSNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market ReviewMay 2, 2025 | uk.finance.yahoo.comThese Cannabis Companies Are Repurchasing SharesMay 2, 2025 | newcannabisventures.comSNDL Inc. (SNDL) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comSNDL 1Q Loss WidensMay 2, 2025 | marketwatch.comSNDL Inc. Earnings Call Highlights Growth and ChallengesMay 1, 2025 | tipranks.comSNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue EstimatesMay 1, 2025 | zacks.comSNDL Reports Record Q1 2025 Results and Strategic InitiativesMay 1, 2025 | tipranks.comSNDL Reports First Quarter 2025 Financial and Operational ResultsMay 1, 2025 | prnewswire.comSNDL Launches Rise Rewards Loyalty ProgramApril 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, ERAS, OLMA, and SNDL Company DescriptionsErasca NASDAQ:ERAS$1.42 -0.04 (-2.41%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.41 -0.01 (-0.42%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Olema Pharmaceuticals NASDAQ:OLMA$5.32 +0.02 (+0.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.26 -0.06 (-1.03%) As of 05/30/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Oramed Pharmaceuticals NASDAQ:ORMP$2.35 +0.12 (+5.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.32 -0.04 (-1.49%) As of 05/30/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.SNDL NASDAQ:SNDL$1.26 -0.04 (-2.72%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.81%) As of 05/30/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
